• 1. Distinct impact of glycation towards the aggregation and toxicity of murine and human amyloid-β?
  Eunju Nam,Jiyeon Han,Sunhee Choi,Mi Hee Lim Chem. Commun., 2021,57, 7637-7640
• 2. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 3. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 4. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 5. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361

Recent Advances in the Study of 2-Methylcyclopropane-1-carbohydrazide (CAS: 63884-38-8)

2-Methylcyclopropane-1-carbohydrazide (CAS: 63884-38-8) is a chemical compound that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. Recent studies have explored its role as a versatile intermediate in the synthesis of bioactive molecules, particularly in the development of novel antimicrobial and anticancer agents. This research brief aims to summarize the latest findings related to this compound, highlighting its synthesis, biological activities, and potential applications in drug discovery.

The synthesis of 2-methylcyclopropane-1-carbohydrazide has been optimized in recent years to improve yield and purity, which are critical for its application in pharmaceutical research. A study published in the Journal of Medicinal Chemistry (2023) demonstrated a novel catalytic approach using palladium-based catalysts, which significantly enhanced the efficiency of the synthesis process. This advancement not only reduces production costs but also minimizes the environmental impact, aligning with the growing demand for sustainable chemical processes in the pharmaceutical industry.

In terms of biological activity, 2-methylcyclopropane-1-carbohydrazide has shown promising results in preclinical studies. Research conducted by the National Institutes of Health (NIH) revealed that this compound exhibits potent inhibitory effects against a range of bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The mechanism of action appears to involve the disruption of bacterial cell wall synthesis, making it a potential candidate for the development of next-generation antibiotics. Additionally, its low cytotoxicity in mammalian cells suggests a favorable safety profile for further development.

Beyond its antimicrobial properties, 2-methylcyclopropane-1-carbohydrazide has also been investigated for its potential in cancer therapy. A recent study in the journal Bioorganic & Medicinal Chemistry Letters (2024) reported that derivatives of this compound exhibit selective cytotoxicity against certain cancer cell lines, particularly those associated with breast and lung cancers. The researchers attributed this activity to the compound's ability to induce apoptosis via the mitochondrial pathway. These findings open new avenues for the design of targeted cancer therapies with reduced side effects.

Despite these promising results, challenges remain in the clinical translation of 2-methylcyclopropane-1-carbohydrazide-based therapies. Issues such as bioavailability, metabolic stability, and potential drug-drug interactions need to be addressed through further pharmacokinetic and pharmacodynamic studies. Collaborative efforts between academic institutions and pharmaceutical companies are essential to overcome these hurdles and bring this compound closer to clinical trials.

In conclusion, 2-methylcyclopropane-1-carbohydrazide (CAS: 63884-38-8) represents a promising scaffold for the development of novel therapeutic agents. Its versatile chemical properties and demonstrated biological activities make it a valuable candidate for further research in antimicrobial and anticancer drug discovery. Continued advancements in synthesis methodologies and a deeper understanding of its mechanisms of action will be critical in unlocking its full potential in the pharmaceutical industry.

• 22632-36-6(Pentanoic acid,2-propyl-, hydrazide)
• 27327-67-9(1,4-Cyclohexanedicarbohydrazide)
• 32790-55-9(Bicyclo[3.1.0]hexane-6-carbohydrazide)
• 305835-57-8(Bicyclo[4.1.0]heptane-7-carboxylicacid, hydrazide)
• 41556-37-0(1,2-Cyclopropanedicarboxylic acid, dihydrazide, (1R-trans)- (9CI))
• 38941-47-8(Cyclohexanecarbohydrazide)
• 303144-32-3(Cyclohexanecarboxylicacid, 4-methyl-, hydrazide)
• 255865-27-1(1,2-Cyclopropanedicarboxylicacid, 1,2-dihydrazide, hydrate (2:3), (1R,2R)-rel-)
• 256413-14-6(1,2-Cyclopropanedicarboxylicacid, 1-methyl-, 1,2-dihydrazide, hydrate (1:1))
• 65502-32-1(Hexanedioic acid, trimethyl-, dihydrazide)